Clinical Trials on WHO Grade III Gliomas

Total 577 results

Beijing Tiantan Hospital
ZhongSheng BioTech Inc.

Recruiting

Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas

WHO Grade III Gliomas | WHO Grade IV Gliomas

China
Susan Chang
GE Healthcare; Sigma-Aldrich; Phillips-Medisize

Recruiting

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Recurrent WHO Grade III Glioma | WHO Grade III Glioma | WHO Grade II Glioma | Recurrent World Health Organization (WHO) Grade II Glioma

United States
University of California, San Francisco
BeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology Consortium

Recruiting

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)

Glioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II Glioma

United States
City of Hope Medical Center
National Cancer Institute (NCI); Food and Drug Administration (FDA)

Active, not recruiting

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III Glioma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Recruiting

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

Glioblastoma | WHO Grade III Glioma | WHO Grade II Glioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

Glioblastoma | WHO Grade III Glioma | WHO Grade II Glioma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BeiGene

Completed

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | IDH1 Mutation | IDH2 Mutation

United States
M.D. Anderson Cancer Center

Recruiting

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

Glioblastoma | Anaplastic Oligoastrocytoma | Oligoastrocytoma | Oligodendroglioma | Anaplastic Oligodendroglioma | WHO Grade III Glioma | Diffuse Astrocytoma, IDH-Wildtype | WHO Grade II Glioma | Anaplastic Astrocytoma, IDH-Wildtype

United States
Frank Lieberman
University of Minnesota

Completed

Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas

High Risk WHO Grade II Glioma | Recurrent/Post-Chemotherapy WHO Grade II Glioma

United States
Thomas Hope

Active, not recruiting

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms (UC-GlioFET)

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Low Grade Glioma | Intracranial Neoplasm | Recurrent World Health Organization (WHO) Grade II Glioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Mind-Body Intervention in Glioma Couples

Glioblastoma | Malignant Glioma | WHO Grade III Glioma | Metastatic Malignant Neoplasm in the Brain | Low Grade Glioma | Partner

United States
Northwestern University
National Cancer Institute (NCI); BrainUp Inc

Not yet recruiting

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Recurrent WHO Grade 2 Glioma | Recurrent Glioblastoma, IDH-Wildtype | Recurrent WHO Grade 3 Glioma | Recurrent WHO Grade 4 Glioma

United States
Children's Hospital Medical Center, Cincinnati

Terminated

Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy

Glioblastoma Multiforme (WHO Grade IV) | Anaplastic Astrocytoma (WHO Grade III)

United States
Massachusetts General Hospital
National Cancer Institute (NCI)

Active, not recruiting

Proton Radiation Therapy for Gliomas

Low Grade Glioma | WHO Grade 3 Glioma With IDH1 Mutation | WHO Grade 3 Glioma With 1p/19q Codeletion

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers

Glioblastoma | Malignant Glioma | WHO Grade III Glioma

United States
Rigel Pharmaceuticals
Nationwide Children's Hospital

Not yet recruiting

Study of Olutasidenib and Temozolomide in HGG

Astrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditions

United States, Australia, United Kingdom, Canada, Germany, Netherlands
National Cancer Institute (NCI)

Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Recurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 Glioma

United States, Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Recurrent Gliosarcoma | Recurrent Anaplastic Astrocytoma | Recurrent Anaplastic Oligoastrocytoma | Recurrent Anaplastic Oligodendroglioma

United States
Nationwide Children's Hospital
Novartis

Not yet recruiting

Study of Ribociclib and Everolimus in HGG and DIPG

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV Glioma

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Nationwide Children's Hospital

Not yet recruiting

Targeted Pediatric High-Grade Glioma Therapy

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV Glioma

United States, Australia, United Kingdom, Canada, Germany, Netherlands
University of Göttingen
Hannover Medical School; Deutsche Kinderkrebsstiftung

Recruiting

International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) (HIT-HGG-2013)

Diffuse Intrinsic Pontine Glioma | Gliomatosis Cerebri | Glioblastoma WHO Grade IV | Diffuse Midline Glioma Histone 3 K27M WHO Grade IV | Anaplastic Astrocytoma WHO Grade III

Germany
University of California, San Francisco
National Institute of Neurological Disorders and Stroke (NINDS); The Chad-Tough... and other collaborators

Recruiting

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent WHO Grade III Glioma | WHO Grade III Glioma

United States, Netherlands, Israel, Australia, New Zealand, Switzerland
University of California, San Francisco
Novartis

Terminated

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

Low Grade Glioma | World Health Organization (WHO) Grade II Astrocytomas | Oligodendrogliomas | Mixed Oligoastrocytomas

United States
Nationwide Children's Hospital
Pfizer

Not yet recruiting

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | WHO Grade III Glioma | WHO Grade IV Glioma | Infant Type Hemispheric Glioma | Diffuse Midline Glioma, H3K27-altered

United States, Australia, Canada, Germany, Netherlands
Galina Velikova
The Leeds Teaching Hospitals NHS Trust; European Organisation for Research...

Completed

Long Term Implications of Rare Brain Tumours'

Quality of Life | Cognitive Impairment | Health-related Quality of Life | Long-term Effects of Cancer Treatment | WHO Grade II Oligodendroglial Tumor | WHO Grade III Oligodendroglial Tumor

Netherlands, United Kingdom
Michael Vogelbaum, MD, PhD
Infuseon Therapeutics, Inc.

Completed

Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma

Malignant Glioma | WHO Grade III or IV Recurrent Glioma

United States
University of California, San Francisco
Novartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...

Recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

High Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II Glioma

United States
Annick Desjardins
Tactical Therapeutics, Inc.

Terminated

Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma

Malignant Glioma (WHO Grade III or IV)

United States
Annick Desjardins
Tactical Therapeutics, Inc.

Terminated

Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure

Malignant Glioma (WHO Grade III or IV)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma

Glioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory Glioma

United States
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

WHO Grade II Glioma

Japan
National Cancer Institute (NCI)

Recruiting

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Recurrent WHO Grade 2 Glioma | Recurrent Glioblastoma, IDH-Wildtype | Recurrent WHO Grade 3 Glioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Glioblastoma | WHO Grade 3 Glioma | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Glioma | Recurrent Cholangiocarcinoma | WHO Grade 2 Glioma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Malignant Glioma | WHO Grade 3 Glioma | Intractable Epilepsy | Seizure Disorder | WHO Grade 2 Glioma

United States
Washington University School of Medicine

Completed

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Astrocytoma, Grade III | Astrocytoma, Grade IV | Grade IV Astrocytoma | Grade III Astrocytoma

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

Glioma | Oligoastrocytoma | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Astrocytoma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | 1p/19q Co-deletion

United States
National Cancer Institute (NCI)

Recruiting

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

Glioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade Glioma

United States
Beijing Tiantan Hospital
Beijing Shijitan Hospital, Capital Medical University; Beijing Neurosurgical...

Unknown

CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas

Grade II/III Glioma

China
Sabine Mueller, MD, PhD
Pacific Pediatric Neuro-Oncology Consortium

Recruiting

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Glioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III Glioma

United States, Australia, Israel, Switzerland
University of Florida
NovoCure Ltd.

Terminated

FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma (FORWARD)

Astrocytoma, Grade III | Astrocytoma, Grade II

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma

Glioma

United States
Erasmus Medical Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Leiden University... and other collaborators

Recruiting

Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes (RIGEL)

Oligodendroglioma | Astrocytoma, Grade III | Astrocytoma, Grade II | Oligodendroglioma, Anaplastic

Netherlands
National Cancer Institute (NCI)

Completed

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Glioma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Oligodendrogliomas | Astrocytoma, Grades II, III and IV

United States
BioMimetix JV, LLC
National Cancer Institute (NCI); Duke Cancer Institute

Active, not recruiting

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 (BMX-HGG)

Glioblastoma | High Grade Glioma | Astrocytoma, Grade III

United States
National Cancer Institute (NCI)

Completed

ZD6474 to Treat Advanced Brain Cancer in Patients

Recurrent High-Grade Gliomas | Malignant Gliomas | Progressive Low-Grade Gliomas

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults (VINILO)

Refractory Low-grade Gliomas | Recurrent Low-grade Gliomas

Austria, Italy, France, Denmark, Netherlands, Spain, Switzerland, United Kingdom
Northwell Health

Withdrawn

Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas

Glioblastoma | Malignant Glioma | Astrocytoma, Grade III | Astrocytoma, Grade IV

United States
Oliver Jonas, PhD

Recruiting

Implantable Microdevice In Primary Brain Tumors

Glioblastoma | Astrocytoma | Anaplastic Oligodendroglioma | Anaplastic Astrocytoma of Brain | Grade III Glioma | Grade IV Glioma | Grade II Glioma | Oligodendroglioma of Brain

United States

Clinical Trials on WHO Grade III Gliomas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations